Loomis, Sayles & Company
TVTX icon

Loomis, Sayles & Company’s Travere Therapeutics TVTX Stock Holding History

Loomis, Sayles & Company’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.8M Buy
470,914
+169,448
+56% +$7.51M 0.03% 202
2026
Q1 		$8.96M Buy
301,466
+62,542
+26% +$1.87M 0.01% 369
2025
Q4 		$9.13M Buy
+238,924
New +$7.77M 0.01% 371
2025
Q3 		– Sell
-439,341
Closed -$6.5M – 764
2025
Q2 		$6.5M Sell
439,341
-308,811
-41% -$5.12M 0.01% 411
2025
Q1 		$13.4M Buy
+748,152
New +$15.2M 0.02% 305
2015
Q4 		– Sell
-132,207
Closed -$2.68M – 1116
2015
Q3 		$2.68M Buy
+132,207
New +$3.92M 0.01% 512

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company's TVTX Position: Q2 2026 in Review

Loomis, Sayles & Company increased its Travere Therapeutics (TVTX) stake by 56% in Q2 2026, buying an estimated $7.51M and bringing the position to 470,914 shares worth $26.8M. The position accounts for 0.03% of the portfolio, ranked #202.

Loomis, Sayles & Company first reported a position in TVTX in Q3 2015 and has held it in 6 quarters since. 319 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Loomis, Sayles & Company held 470,914 shares of Travere Therapeutics worth $26.8M as of Q2 2026.
  • Loomis, Sayles & Company bought 169,448 Travere Therapeutics shares in Q2 2026, an estimated $7.51M.
  • Travere Therapeutics made up 0.03% of Loomis, Sayles & Company's portfolio in Q2 2026, its #202 holding.
  • Loomis, Sayles & Company first reported a position in Travere Therapeutics in Q3 2015 and has held it in 6 quarters since.
  • 319 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.